Spots Global Cancer Trial Database for Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Official Title: An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
Study ID: NCT02792725
Conditions
Interventions
Study Description
Brief Summary: The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pacific Cancer Care, Monterey, California, United States
UCLA Medical Center, Santa Monica, California, United States
Orlando Health, Inc, Orlando, Florida, United States
Rush University Medical Center, Chicago, Illinois, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Minnesota Medical Center, Fairview Lakes, Wyoming, Minnesota, United States
Saint Luke's Cancer Institute, Kansas City, Missouri, United States
Memorial Sloan Kettering Cancer Center, Commack, New York, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
West Virginia University Hospital, Morgantown, West Virginia, United States
Contact Details
Name: Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
